Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes

Stock Information for Longeveron Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Longeveron Inc.

Century Therapeutics to Participate in Upcoming Investor Conferences in March
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.